Immunotherapy may let some bladder cancer patients keep their bladder

NCT ID NCT05406713

First seen Apr 17, 2026 · Last updated May 23, 2026 · Updated 5 times

Summary

This study tests whether the immunotherapy drug pembrolizumab can shrink muscle-invasive bladder cancer enough to avoid removing the bladder. About 46 adults with localized bladder cancer will receive pembrolizumab before standard treatments. Those whose cancer completely responds may continue on pembrolizumab and skip surgery or radiation, while others proceed with usual care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana, 46202, United States

  • University of New Mexico Comprehensive Cancer Center

    Albuquerque, New Mexico, 87102, United States

Conditions

Explore the condition pages connected to this study.